A5057437410- Inflammatory Bowel Disease
- Clinical Nutrition and Gastroenterology
- Microscopic Colitis
- Central Venous Catheters and Hemodialysis
- Dialysis and Renal Disease Management
- Nutrition and Health in Aging
- Abdominal Surgery and Complications
- Liver Disease and Transplantation
- Acute Lymphoblastic Leukemia research
- FOXO transcription factor regulation
- Infective Endocarditis Diagnosis and Management
- Intestinal and Peritoneal Adhesions
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
- Acute Kidney Injury Research
- Intestinal Malrotation and Obstruction Disorders
- Colorectal and Anal Carcinomas
- Immunodeficiency and Autoimmune Disorders
- Pregnancy and Medication Impact
- Genetic factors in colorectal cancer
- Autoimmune and Inflammatory Disorders
- Venous Thromboembolism Diagnosis and Management
- Stoma care and complications
- Potassium and Related Disorders
- Mycobacterium research and diagnosis
Nottingham University Hospitals NHS Trust
2024
University of Liverpool
2014-2023
Aintree University Hospitals NHS Foundation Trust
2021-2023
Royal Liverpool University Hospital
2014-2022
Royal Liverpool and Broadgreen University Hospital NHS Trust
2014-2020
Broadgreen Hospital
2020
GTx (United States)
2019
Salford Royal NHS Foundation Trust
2012-2017
University of Manchester
2011-2015
University Teaching Hospital
2015
Abstract Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel diseases [IBD] patients. A subcutaneous [SC] formulation of [CT-P13] has recently been shown to be as effective IV after two doses induction in randomised trial, but there are no data support elective switching patients on maintenance therapy. We aimed assess the effectiveness an programme SC CT-P13 treated with infliximab. Methods Patients established infliximab, who switched CT-P13, were...
Background: Catheter‐related bloodstream infections (CRBSIs) are a serious complication in the provision of home parenteral nutrition (HPN). Antibiotic salvage central venous catheters (CVCs) CRBSI is recommended; however, this based on limited reports. We assessed efficacy antibiotic CRBSIs HPN patients. Materials and Methods : All confirmed occurring patients receiving national intestinal failure unit (IFU), between 1993 2011, were analyzed. A standardized protocol involving urokinase CVC...
The transcription factor FOXM1 is an important regulator of the cell cycle through controlling periodic gene expression during G2 and M phases. One key target for encoding protein kinase PLK1 itself acts in a positive feedback loop to phosphorylate activate FOXM1. Both have been shown be overexpressed variety different tumour types. We used combination RT–PCR, western blotting, tissue microarrays metadata analysis microarray data study whether FOXM1-PLK1 regulatory axis upregulated...
Optimal levels of the thiopurine metabolite, 6-thioguanine nucleotides [6-TGN] correlate with remission inflammatory bowel disease [IBD]. Apart from variations in methyl transferase [TPMT] gene, little is known about other predictors 6-TGN levels. Obesity adversely affects response to infliximab and adalimumab clinical course IBD, but interaction thiopurines obesity. We investigated relationship between body mass index [BMI] sought examine levels.This retrospective cohort study included...
Introduction Antitumour necrosis factor (TNF) agents and vedolizumab are used to treat ulcerative colitis (UC) but the response is variable there little data on comparative effectiveness. Apart from previous exposure anti-TNF agents, predictors of have not been identified. We aimed (i) compare efficacy in UC (ii) investigate utility clinical biochemical parameters predicting response. Patients methods commencing any biological therapy for ambulant were included. Disease activity was...
<h3>Introduction</h3> Catheter-related blood stream infections (CRBSI) are a serious and life-threatening complication in the provision of HPN. European guidelines recommend antibiotic salvage central venous catheters (CVCs) with CRBSI, wherever possible, to minimise repeated catheter replacement preserve access, but this is based on limited reported evidence.<sup>1</sup> <h3>Methods</h3> Data were analysed from prospectively-maintained register all confirmed CRBSIs occurring patients HPN...
Gastric cancers present late in life with advanced disease and carry a poor prognosis. Polo-like Kinase 1 (PLK1) is mitotic kinase regulatory functions during G2/M mitosis the cell cycle. In mammalian cells, there an intricate co-regulatory relationship between PLK1 forkhead transcription factor FOXM1. It has been demonstrated that individually either or FOXM1 expression predicts poorer survival. However, co-expression of both these markers gastric adenocarcinomas not reported previously. We...
Various physician- and patient-reported instruments exist for quantification of disease activity in inflammatory bowel diseases (IBD) but none are widely used routine clinical practice. A simple outcome measure might help inform decision making. We evaluated a 0 to 10 score IBD (IBD-10) by correlation with conventional multicomponent indices.A single-center prospective cross-sectional study was conducted ambulant patients IBD. Patients were asked verbally rate the control Crohn's (CD) or...
<h3>Introduction</h3> Home parenteral nutrition (HPN) is an essential treatment modality for patients with Type 3 intestinal failure (IF), but long term data on the factors associated HPN dependence and survival are limited. <h3>Methods</h3> Medical records of IF who received more than months from a national Unit between 1978 2011 were reviewed. Kaplan–Meier curves Cox regression analysis performed to identify poor prognosis. <h3>Results</h3> Case notes 547 The overall probability was 89%,...
<h3>Introduction</h3> Immunogenicity is a common problem associated with anti-tumour necrosis factor (TNF) therapy and often loss of clinical response. Concomitant immunomodulatory reduces the rate anti-drug antibody (ADA) formation infliximab better outcomes.<sup>1</sup> However, impact immunomodulator initiation specifically to reverse established ADA has not been adequately investigated. Current guidelines recommend switching anti-TNF agent or class switch in presence titre >9 u/ml....